Phaseline

Companies › Serina Therapeutics

Serina Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SER-252 (PEOZ-apomorphine)
Dopamine receptor agonist (D1-like and D2-like dopamine receptors)
DRD1, DRD2, DRD3, DRD4, DRD5Phase 1PARKINSON DISEASE (Disorder)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07422675SER-252 (PEOZ-apomorphine)Phase 1PARKINSON DISEASE (Disorder)NeurologyJan 2027

From the company's SEC filings

Cash of $23m on 2026-06-30; operating cash outflow about $23m a year; runway about 12 months at that burn, to Jul 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

DRD1 (1) DRD2 (1) DRD3 (1) DRD4 (1) DRD5 (1)

Companies with the same targets

Boryung Pharmaceutical MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals LB Pharmaceuticals Gedeon Richter Anxo Pharmaceutical Mapi Pharma AbbVie Emalex Biosciences Prilenia Changchun GeneScience Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.